Deutsch English Français

Contact

EP2187927

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP2187927

EP2187927 - USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH FOR TREATING STREPTOCOCCUS PNEUMONIAE INFECTION [Right-click to bookmark this link]
Former [2010/21]	USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH AS A THERAPEUTIC AGENT
	[2011/33]
Status	The application is deemed to be withdrawn Status updated on 15.06.2012 Database last updated on 08.04.2026
Most recent event Tooltip	15.06.2012	Application deemed to be withdrawn	published on 18.07.2012 [2012/29]
Applicant(s)	For all designated states Mondobiotech Laboratories AG Herrengasse 21 9490 Vaduz / LI
	[2010/21]
Inventor(s)	01 / BEVEC, Dorian Kriegerstrasse 62 82110 Germering / DE
	02 / CAVALLI, Fabio Via Pasquée 23 CH-6925 Gentilino / CH
	03 / CAVALLI, Vera Via Pasquée 23 CH-6925 Gentilino / CH
	04 / BACHER, Gerald Masurenweg 5 82110 Germering / DE
	[2011/41]
Former [2010/21]	01 / BEVEC, Dorian Kriegerstrasse 62 82110 Germering / DE
	02 / CAVALLI, Fabio ViaPasquée 23 CH-6925 Gentilino / CH
	03 / CAVALLI, Vera Via Pasquée 23 CH-6925 Gentilino / CH
	04 / BACHER, Gerald Masurenweg 5 82110 Germering / DE
Representative(s)	Arth, Hans-Lothar ABK Patent Attorneys Jasminweg 9 14052 Berlin / DE
	[N/P]
Former [2010/21]	Arth, Hans-Lothar ABK Patent Attorneys Jasminweg 9 14052 Berlin / DE
Application number, filing date	08802002.9	09.09.2008
	[2010/21]
	WO2008EP07441
Priority number, date	EP20070017766	11.09.2007 Original published format: EP 07017766
	[2010/21]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2009039960
	Date:	02.04.2009
	Language:	EN
	[2009/14]
	Type:	A1 Application with search report
	No.:	EP2187927
	Date:	26.05.2010
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 02.04.2009 takes the place of the publication of the European patent application.
	[2010/21]
Search report(s)	International search report - published on:	EP	02.04.2009
Classification	IPC:	A61K38/26, A61P31/04	[2011/33]
	CPC:	A61K38/22 (EP,US); A61K38/26 (EP,KR,US); A23C9/1526 (KR); A23L33/18 (EP,KR,US); A23L33/40 (EP,KR,US); A61K38/10 (KR); (+) A61K9/08 (KR); A61K9/19 (KR); A61P1/00 (EP); A61P1/02 (EP); A61P1/04 (EP); A61P1/16 (EP); A61P1/18 (EP); A61P11/00 (EP); A61P11/02 (EP); A61P11/04 (EP); A61P11/06 (EP); A61P11/08 (EP); A61P11/16 (EP); A61P13/02 (EP); A61P13/12 (EP); A61P15/00 (EP); A61P15/02 (EP); A61P15/06 (EP); A61P15/08 (EP); A61P15/10 (EP); A61P17/00 (EP); A61P17/02 (EP); A61P17/04 (EP); A61P17/06 (EP); A61P17/08 (EP); A61P17/12 (EP); A61P19/00 (EP); A61P19/02 (EP); A61P19/04 (EP); A61P19/06 (EP); A61P19/08 (EP); A61P19/10 (EP); A61P21/00 (EP); A61P21/04 (EP); A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP); A61P25/08 (EP); A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP); A61P25/32 (EP); A61P25/34 (EP); A61P25/36 (EP); A61P27/00 (EP); A61P27/02 (EP); A61P27/06 (EP); A61P27/12 (EP); A61P27/16 (EP); A61P29/00 (EP); A61P3/00 (EP); A61P3/02 (EP); A61P3/04 (EP); A61P3/06 (EP); A61P3/08 (EP); A61P3/10 (EP); A61P3/14 (EP); A61P31/00 (EP); A61P31/04 (EP); A61P31/06 (EP); A61P31/08 (EP); A61P31/10 (EP); A61P31/12 (EP); A61P31/14 (EP); A61P31/16 (EP); A61P31/18 (EP); A61P31/20 (EP); A61P31/22 (EP); A61P33/00 (EP); A61P33/02 (EP); A61P33/04 (EP); A61P33/06 (EP); A61P33/08 (EP); A61P33/10 (EP); A61P33/14 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP); A61P5/00 (EP); A61P7/02 (EP); A61P7/04 (EP); A61P7/06 (EP); A61P7/12 (EP); A61P9/00 (EP); A61P9/02 (EP); A61P9/04 (EP); A61P9/06 (EP); A61P9/10 (EP); A61P9/12 (EP); A61P9/14 (EP); A23V2002/00 (EP,KR,US); Y02A50/30 (EP,KR,US) (-)
	C-Set:	A61K38/22, A61K2300/00 (EP,US); A61K38/26, A61K2300/00 (US,EP); A23V2002/00, A23V2200/308, A23V2200/318, A23V2200/322, A23V2200/324, A23V2200/326, A23V2250/55 (US,EP)
	Former IPC [2010/21]	A61K38/17, A61K38/10, A61K38/08, A61P3/00, A61P9/00, A61P11/00, A61P25/28, A61P31/20, A61P35/00, A61P37/00, A61P31/04
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/21]
Title	German:	VERWENDUNG DES PEPTIDS HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALLEIN ODER IN KOMBINATION MIT DEM PEPTID GLY-ARD-GLY-ASP-ASN-PRO-OH ZUR BEHANDLUNG VON STREPTOKOKKUS PNEUMONIAE INFEKTIONEN	[2011/33]
	English:	USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH FOR TREATING STREPTOCOCCUS PNEUMONIAE INFECTION	[2011/33]
	French:	UTILISATION DU PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE SEUL OU COMBINÉ AU PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH POUR TRAITER LES INFECTIONS A STREPTOCOCCUS PNEUMONIAE	[2011/33]
	Former [2010/21]	VERWENDUNG DES PEPTIDS HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALLEIN ODER IN KOMBINATION MIT DEM PEPTID GLY-ARD-GLY-ASP-ASN-PRO-OH ALS THERAPEUTISCHES MITTEL
	Former [2010/21]	USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH AS A THERAPEUTIC AGENT
	Former [2010/21]	UTILISATION DU PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE SEUL OU COMBINÉ AU PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH EN TANT QU'AGENT THÉRAPEUTIQUE
Entry into regional phase	05.03.2010	National basic fee paid
	05.03.2010	Designation fee(s) paid
	05.03.2010	Examination fee paid
Examination procedure	05.03.2010	Amendment by applicant (claims and/or description)
	05.03.2010	Examination requested [2010/21]
	20.10.2010	Despatch of a communication from the examining division (Time limit: M06)
	23.02.2011	Reply to a communication from the examining division
	14.09.2011	Communication of intention to grant the patent
	25.01.2012	Application deemed to be withdrawn, date of legal effect [2012/29]
	28.02.2012	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2012/29]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.10.2010
Fees paid	Renewal fee
	21.08.2010	Renewal fee patent year 03
	Penalty fee
	Additional fee for renewal fee
	30.09.2011	04 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X] WO9937315 (BAI JANE PEI FAN et al.)
		[A] WO9308818 (UNIV SOUTHERN CALIFORNIA et al.)
		[A] DE19529909 (FRESENIUS AG et al.)
		[X] NICHOLSON L B ET AL: "An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.", IMMUNITY OCT 1995, vol. 3, no. 4, October 1995 (1995-10-01), pages 397 - 405, XP002513738, ISSN: 1074-7613 DOI: http://dx.doi.org/10.1016/1074-7613(95)90169-8
	by applicant	US4474752
		US4474753
		US4478822
		WO2007104173

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.